Skip to main content
Sign in Create a free account
Varsity Tutors
Sign in

OTC Medications And Supplements - NAPLEX

  1. A 62-year-old female (70 kg) asks about taking an OTC "extra strength" pain reliever for knee osteoarthritis. Medical history includes atrial fibrillation and prior gastrointestinal bleed; she takes warfarin (goal INR 2–3) and omeprazole 20 mg daily. Labs today: INR 2.6 (therapeutic). She currently uses fish oil 2 g/day and occasionally takes ibuprofen 400 mg for pain; no known drug allergies. Which potential interaction should be assessed as most clinically significant?
    Answer: Ibuprofen increasing bleeding risk when combined with warfarin This question evaluates the ability to identify clinically significant drug interactions with warfarin and OTC products. The key patient-specific factors are the patient's anticoagulation therapy (warfarin with therapeutic INR), history of gastrointestinal bleed, and occasional ibuprofen use. Ibuprofen increasing bleeding risk when combined with warfarin (A) is the most clinically significant interaction because NSAIDs like ibuprofen not only increase INR through platelet inhibition but also directly increase GI bleeding risk, especially concerning given her bleeding history. Omeprazole (B) does not decrease warfarin absorption or lower INR; it may actually slightly increase INR. Fish oil (C) does not induce hepatic enzymes or cause loss of warfarin efficacy; it may have mild antiplatelet effects. Acetaminophen (D) can actually increase INR with regular high doses, not decrease it. The clinical framework is that NSAIDs should be avoided in patients on warfarin, especially those with bleeding history, and acetaminophen is the preferred OTC analgesic.
  2. A 29-year-old man (90 kg) requests an OTC cold product for congestion and cough. He takes phenelzine for depression (monoamine oxidase inhibitor) and has no allergies. Current OTC/supplements include vitamin C 1,000 mg daily and he used a friend's "maximum strength" decongestant yesterday. Which action should the pharmacist take regarding this OTC product?
    Answer: Avoid oral decongestants and dextromethorphan; recommend saline nasal spray and guaifenesin with hydration This question tests OTC cold product selection in patients on monoamine oxidase inhibitors. The key patient-specific factor is phenelzine use, which contraindicates sympathomimetics and certain antitussives due to hypertensive crisis risk. Avoiding oral decongestants and dextromethorphan while recommending saline nasal spray and guaifenesin with hydration is best because it provides symptom relief without interaction risks, focusing on non-pharmacologic and safe expectorant options. Pseudoephedrine (A) and phenylephrine (D) are suboptimal as they can cause severe hypertension with MAOIs, while dextromethorphan (B) risks serotonin syndrome. A common misconception is that all OTC cold products are safe, but MAOI interactions are critical. Pharmacists should use interaction checkers for MAOI patients. Guidelines emphasize patient education on avoiding sympathomimetics and serotonergics for at least 2 weeks post-MAOI discontinuation.
  3. A 48-year-old woman (73 kg) asks for an OTC product for frequent headaches. She reports using an OTC combination product containing acetaminophen/aspirin/caffeine, 2 tablets up to 4 times daily, nearly every day for the past month. Medical history: gastroesophageal reflux disease; allergies: none. Which action should the pharmacist take regarding this OTC product?
    Answer: Assess for medication-overuse headache and recommend limiting acute analgesic use; refer for evaluation of frequent headaches This question tests recognition of medication-overuse headache from OTC analgesics. The key patient-specific factor is frequent use of acetaminophen/aspirin/caffeine combination, potentially causing rebound headaches. Assessing for overuse and recommending limitation with referral is best because it addresses the cycle and prompts professional evaluation. Continuing or switching to higher doses (A, C) perpetuates overuse; adding ibuprofen (D) compounds risks. A clinical pearl is limiting acute treatments to <10 days/month. Guidelines from AHS recommend tracking usage and preventive strategies.
  4. A 52-year-old female (72 kg) asks about an OTC potassium supplement because she read it can help blood pressure. Medical history includes hypertension and chronic kidney disease stage 3a; medications include lisinopril 20 mg daily and hydrochlorothiazide 25 mg daily. Recent labs: serum potassium 5.3 mEq/L (normal 3.5–5.0), serum creatinine 1.4 mg/dL. She also takes a salt substitute at home and a daily vitamin D supplement; no known drug allergies. Which action should the pharmacist take regarding this OTC product?
    Answer: Advise against potassium supplementation and recommend contacting the prescriber due to hyperkalemia risk with lisinopril and kidney disease This question tests recognition of hyperkalemia risk with OTC potassium supplements. The key patient-specific factors are elevated serum potassium (5.3 mEq/L), CKD stage 3a, concurrent ACE inhibitor use (lisinopril), and use of salt substitute (which contains potassium). Advising against potassium supplementation and recommending prescriber contact (C) is correct because the patient already has hyperkalemia, and adding OTC potassium could cause dangerous cardiac arrhythmias. OTC potassium supplements (A) would worsen hyperkalemia. Salt substitutes (B) contain potassium chloride and are already contributing to elevated levels. The statement about hydrochlorothiazide always causing low potassium (D) is incorrect, especially when combined with potassium-sparing medications like ACE inhibitors. The clinical framework is that patients with CKD, especially those on ACE inhibitors or ARBs, should avoid potassium supplements and salt substitutes unless specifically directed by their physician with close monitoring.
  5. A 66-year-old woman (74 kg) takes apixaban 5 mg twice daily for venous thromboembolism and asks for an OTC product for new-onset low back pain after gardening. Medical history: hypertension; allergies: none. Current OTC/supplements include naproxen 220 mg twice daily started yesterday and glucosamine/chondroitin. Which action should the pharmacist take regarding this OTC product?
    Answer: Recommend switching to acetaminophen and/or topical diclofenac; avoid oral NSAIDs due to increased bleeding risk with apixaban This question tests OTC NSAID use with anticoagulants. The key patient-specific factor is apixaban increasing bleeding risk with NSAIDs like naproxen. Recommending switch to acetaminophen or topical diclofenac is best because they offer analgesia with lower systemic bleeding risks. Continuing with aspirin (A) or naproxen (C) heightens hemorrhage; stopping apixaban (D) risks thrombosis. A clinical pearl is using HAS-BLED for assessment. Guidelines advise avoiding oral NSAIDs with DOACs, preferring alternatives.
  6. A 43-year-old woman (59 kg) asks about an OTC supplement to improve depression symptoms. She takes fluoxetine 40 mg daily and has no allergies. Current OTC/supplements include St. John's wort started 1 week ago and melatonin. Which action should the pharmacist take regarding this supplement use?
    Answer: Advise stopping St. John's wort due to risk of serotonin syndrome and drug interactions with fluoxetine This question tests supplement interactions with SSRIs. The key patient-specific factor is St. John's wort inducing CYP3A4 and risking serotonin syndrome with fluoxetine. Advising discontinuation is best because it prevents reduced efficacy and toxicity. Continuing or reducing fluoxetine (B, C) risks imbalance; adding dextromethorphan (D) adds serotonergic risk. Pharmacists should use evidence-based resources. Guidelines warn against St. John's wort with antidepressants due to interactions.
  7. A 47-year-old woman (64 kg) with hypothyroidism on levothyroxine 100 mcg daily asks about starting an OTC supplement for "stronger hair and nails." She currently takes biotin 10,000 mcg daily and a multivitamin; allergies: none. Recent labs: thyroid-stimulating hormone 2.0 mIU/L (0.4–4.0). What is the most important counseling point for this OTC product?
    Answer: Biotin can interfere with certain lab tests; tell the patient to inform the lab/clinician and consider holding biotin before blood draws This question tests counseling on biotin use in thyroid patients. The key patient-specific factor is high-dose biotin interfering with thyroid lab assays, potentially skewing TSH results. Advising to inform lab/clinician and hold biotin before blood draws is most important because it ensures accurate monitoring of hypothyroidism. Requiring co-administration with levothyroxine (B) is incorrect as it does not improve absorption; contraindication claims (C) are misconceptions. Rapid hair regrowth (D) lacks evidence. A clinical pearl is biotin's interference with immunoassays. A decision framework involves checking supplement doses and lab timing per FDA warnings.
  8. A 68-year-old man (82 kg) requests an OTC product for knee osteoarthritis pain. He takes lisinopril 20 mg daily and hydrochlorothiazide 25 mg daily for hypertension and has chronic kidney disease stage 3 (serum creatinine 1.8 mg/dL [0.6–1.3], estimated glomerular filtration rate 45 mL/min/1.73 m2^2). Current OTC/supplements include ibuprofen 400 mg three times daily for the past week and a daily multivitamin; allergy: none. Which action should the pharmacist take regarding this OTC product?
    Answer: Recommend acetaminophen 650 mg every 6 hours as needed (maximum 3,000 mg/day) and avoid routine NSAID use This question tests patient-centered OTC medication management for osteoarthritis pain in patients with comorbidities. The key patient-specific factors are chronic kidney disease stage 3, hypertension treated with lisinopril and hydrochlorothiazide, and current ibuprofen use, which increase the risk of NSAID-induced renal injury. Recommending acetaminophen 650 mg every 6 hours as needed (maximum 3,000 mg/day) and avoiding routine NSAID use is the best choice because acetaminophen provides effective analgesia with a lower risk of nephrotoxicity and blood pressure elevation in this population. Continuing ibuprofen with food (A) is suboptimal as it does not mitigate the renal risks associated with chronic NSAID use in CKD, while switching to naproxen (B) introduces a similar long-acting NSAID that could further impair renal function. Adding aspirin (D) is incorrect because it adds another NSAID-like agent, increasing risks of gastrointestinal bleeding and renal harm without improving efficacy over monotherapy. A clinical pearl is to always evaluate renal function and concurrent medications when selecting OTC analgesics. Guidelines such as those from the American College of Rheumatology recommend acetaminophen as first-line for osteoarthritis in patients with CKD to prioritize safety.
  9. A 74-year-old male (78 kg) with chronic kidney disease stage 4 (estimated creatinine clearance 22 mL/min) asks about an OTC magnesium supplement for leg cramps. Medical history includes heart failure and hypertension; medications include furosemide 40 mg daily, losartan 50 mg daily, and calcium carbonate 500 mg with meals. Recent labs: serum magnesium 2.2 mg/dL (normal 1.7–2.2), potassium 4.6 mEq/L (normal 3.5–5.0). Which action should the pharmacist take regarding this OTC product?
    Answer: Advise against routine magnesium supplementation and recommend nonpharmacologic measures; refer to prescriber if symptoms persist This question assesses appropriate OTC supplement recommendations in advanced chronic kidney disease (CKD). The key patient-specific factors are stage 4 CKD (CrCl 22 mL/min), normal serum magnesium level (2.2 mg/dL), and concurrent furosemide use. Advising against routine magnesium supplementation (C) is correct because patients with advanced CKD have impaired magnesium excretion, and his level is already at the upper limit of normal. Magnesium oxide (A) and magnesium citrate (B) are both contraindicated in severe renal impairment due to accumulation risk and potential for hypermagnesemia. Potassium supplementation (D) is inappropriate and dangerous given normal potassium levels and CKD. The clinical framework is that magnesium supplementation should be avoided in CKD stages 4-5 unless specifically directed by a nephrologist, and nonpharmacologic measures (stretching, hydration, addressing electrolyte imbalances) should be tried first for leg cramps.
  10. A 57-year-old man (83 kg) with hypertension controlled on amlodipine asks about using an OTC supplement for erectile dysfunction. He has no allergies and denies nitrate use. Current OTC/supplements include yohimbe and ginseng. Which action should the pharmacist take regarding this supplement use?
    Answer: Recommend avoiding yohimbe due to potential to increase blood pressure and cause adverse effects; refer for evaluation of erectile dysfunction This question evaluates the pharmacist's role in patient-centered counseling on OTC supplements for erectile dysfunction (ED) in individuals with comorbidities like hypertension. The key patient-specific factor is the patient's controlled hypertension on amlodipine and his use of yohimbe, which poses risks due to its sympathomimetic effects. Choice B is the best action because yohimbe can elevate blood pressure, leading to adverse cardiovascular effects, making it unsafe for hypertensive patients; referring for professional ED evaluation ensures appropriate, evidence-based treatment. Choice A is incorrect as yohimbe lacks robust evidence for efficacy and does indeed affect blood pressure, representing a common misconception about unregulated supplements. Choices C and D are suboptimal; doubling yohimbe and stopping amlodipine risks severe hypertension, while adding pseudoephedrine could exacerbate blood pressure elevation without safely enhancing effects. A useful clinical pearl is to screen supplements for contraindications in chronic conditions, using frameworks like the American Heart Association guidelines for ED management in cardiovascular patients. Pharmacists should promote evidence-based alternatives and encourage physician consultation to balance safety and patient goals.
  11. A 45-year-old woman (70 kg) asks for an OTC medication for heartburn occurring 3–4 days per week. She takes omeprazole 20 mg daily prescribed for gastroesophageal reflux disease and clopidogrel 75 mg daily after a recent coronary stent; allergies: none. OTC/supplements include calcium carbonate chewables as needed and St. John's wort for mood. Which potential interaction should be assessed as most clinically significant?
    Answer: St. John's wort reducing clopidogrel effectiveness via enzyme induction This question tests the identification of clinically significant drug-supplement interactions in patients on antiplatelet therapy. The key patient-specific factor is the use of St. John's wort with clopidogrel, which can lead to reduced antiplatelet efficacy. St. John's wort reducing clopidogrel effectiveness via enzyme induction is the most clinically significant interaction because it induces CYP3A4, potentially decreasing clopidogrel activation and increasing thrombotic risk post-stent. Calcium carbonate increasing clopidogrel absorption (B) is incorrect as it does not affect absorption and may actually decrease it if taken concurrently, while omeprazole increasing clopidogrel activation (C) is a misconception since PPIs like omeprazole inhibit CYP2C19, reducing activation. Calcium carbonate causing serotonin syndrome with St. John's wort (D) is suboptimal as this combination does not pose that risk, which is more associated with serotonergic drugs. Pharmacists should screen for herbal interactions using tools like natural product databases. A decision framework involves assessing interaction severity and monitoring needs, such as INR or platelet function, when supplements are added to critical therapies.
  12. A 56-year-old female (66 kg) with type 2 diabetes asks if she should start an OTC cinnamon supplement to lower her hemoglobin A1c. She takes metformin 1,000 mg twice daily and empagliflozin 10 mg daily; she already uses a daily multivitamin and omega-3 supplement. Recent labs: hemoglobin A1c 8.1% (goal <7%), fasting glucose 165 mg/dL. No known drug allergies. What is the best recommendation for this supplement use?
    Answer: Advise that evidence for meaningful A1c reduction is limited; prioritize medication adherence, lifestyle changes, and prescriber follow-up This question tests evidence-based assessment of dietary supplements for diabetes management. The key patient-specific factor is suboptimal glycemic control (A1c 8.1%) despite dual antidiabetic therapy. Advising that evidence is limited and prioritizing proven interventions (C) is correct because while some studies show modest glucose-lowering effects with cinnamon, the evidence for clinically meaningful A1c reduction is inconsistent and the effect size is small (<0.5% reduction). Recommending cinnamon as first-line therapy (A) or claiming it reduces A1c by 2% (B) overstates the evidence. Combining with aspirin (D) has no basis and adds bleeding risk. The clinical pearl is that dietary supplements should never replace proven diabetes medications, and patients with suboptimal control need medication optimization, lifestyle counseling, and close medical follow-up rather than unproven supplements.
  13. A 61-year-old woman (72 kg) asks for help choosing an OTC pain reliever for headaches. She reports taking acetaminophen 1,000 mg every 6 hours for the past 3 days and also uses an OTC "cold and flu" product containing acetaminophen. Medical history: nonalcoholic fatty liver disease; allergies: none. Which action should the pharmacist take regarding this OTC product?
    Answer: Identify duplicate acetaminophen therapy and counsel to limit total acetaminophen to a maximum of 3,000 mg/day from all sources This question tests recognition of acetaminophen overdose risk from multiple sources. The key patient-specific factor is liver disease increasing susceptibility to acetaminophen hepatotoxicity, with duplicate therapy identified. Identifying duplicate therapy and counseling to limit total acetaminophen to 3,000 mg/day is best because it prevents overdose while allowing safe use for headaches. Reinforcing unlimited safety (A) is a dangerous misconception, as doses over 4,000 mg/day risk toxicity. Switching to higher-dose acetaminophen (C) or adding ibuprofen (D) could exceed limits or add NSAID risks. A clinical pearl is to calculate total daily acetaminophen from all products. A decision framework includes using liver function tests to guide maximum doses in at-risk patients.
  14. A 5-year-old female (18 kg) is brought to the pharmacy for fever and sore throat for 1 day. The caregiver has been giving acetaminophen 160 mg/5 mL oral liquid at 10 mL every 4 hours around the clock. The child takes a daily gummy multivitamin; no medical problems; allergy: none. Which action should the pharmacist take regarding this OTC product?
    Answer: Reduce to acetaminophen 7.5 mL every 6 hours as needed and avoid exceeding 5 doses in 24 hours This question tests pediatric acetaminophen dosing and safety considerations. The key patient-specific factors are the child's weight (18 kg), age (5 years), and current dosing regimen of 10 mL every 4 hours around the clock. Reducing to 7.5 mL every 6 hours as needed (C) is correct because the current regimen provides 320 mg every 4 hours, which could exceed the maximum daily dose of 75 mg/kg/day (1,350 mg for this 18 kg child) if given 6 times daily. The correct dose is 10-15 mg/kg every 4-6 hours, which equals 180-270 mg per dose for this child, making 7.5 mL (240 mg) appropriate. Continuing the current regimen (A) risks exceeding daily maximum. Adding ibuprofen (B) is unnecessary if acetaminophen is dosed correctly. Aspirin (D) should be avoided in children due to Reye's syndrome risk. The clinical pearl is to always calculate pediatric doses based on weight (10-15 mg/kg/dose) and ensure the total daily dose doesn't exceed 75 mg/kg/day or 5 doses in 24 hours.
  15. A 54-year-old man (84 kg) with atrial fibrillation on warfarin (target international normalized ratio 2–3) asks about starting an OTC supplement for "memory and circulation." His international normalized ratio last week was 2.4; allergies: none. Current OTC/supplements include ginkgo biloba 120 mg daily started 3 days ago and fish oil 1,000 mg daily. Which action should the pharmacist take regarding this supplement use?
    Answer: Advise discontinuing ginkgo biloba due to increased bleeding risk with warfarin This question tests management of supplement interactions with anticoagulants. The key patient-specific factor is ginkgo biloba's antiplatelet effects combined with warfarin, increasing bleeding risk. Advising discontinuation of ginkgo biloba is best because it prevents additive anticoagulation, maintaining stable INR and safety. Doubling ginkgo (B) worsens the risk, while skipping warfarin (C) disrupts therapeutic anticoagulation. Switching to aspirin (D) is suboptimal as it still interacts with ginkgo and may not suit atrial fibrillation management. A clinical pearl is to monitor INR frequently when starting/stopping supplements. A decision framework involves assessing bleeding risk using HAS-BLED scores and counseling on evidence-based alternatives.
  16. A 45-year-old female (63 kg) requests advice about an herbal product for mood. Medical history includes major depressive disorder; she takes sertraline 100 mg daily and uses melatonin 5 mg at bedtime. She recently started St. John's wort 300 mg three times daily "because it's natural." No known drug allergies; no pertinent labs. Which action should the pharmacist take regarding this OTC product?
    Answer: Recommend discontinuing St. John's wort due to risk of serotonin syndrome and drug interactions This question tests knowledge of herbal-drug interactions and appropriate counseling for psychiatric medications. The key patient-specific factor is concurrent use of sertraline (an SSRI) with St. John's wort, which has both serotonergic activity and CYP450 enzyme induction properties. Recommending discontinuation of St. John's wort (B) is correct because it poses dual risks: serotonin syndrome when combined with SSRIs and reduced sertraline levels through CYP3A4 induction. Separating doses by 2 hours (A) does not prevent these systemic interactions. Adding diphenhydramine (C) would not counteract stimulation and adds unnecessary anticholinergic burden. Increasing sertraline while continuing St. John's wort (D) is dangerous and could precipitate serotonin syndrome. The clinical pearl is that St. John's wort should be avoided with all antidepressants due to both pharmacodynamic (serotonin syndrome) and pharmacokinetic (enzyme induction) interactions.
  17. A 39-year-old male (90 kg) wants an OTC product for a cold (nasal congestion, headache). He reports taking a "daytime severe cold" combination product every 4 hours and also taking acetaminophen 1,000 mg every 6 hours for body aches. Medical history: nonalcoholic fatty liver disease; he drinks 2–3 beers nightly; no known drug allergies. Which action should the pharmacist take regarding this OTC product?
    Answer: Assess total daily acetaminophen from all products and recommend avoiding duplicate acetaminophen to reduce hepatotoxicity risk This question evaluates recognition of duplicate acetaminophen exposure from combination products. The key patient-specific factors are nonalcoholic fatty liver disease, regular alcohol consumption (2-3 beers nightly), and concurrent use of both a combination cold product and standalone acetaminophen. Assessing total daily acetaminophen intake (B) is correct because many OTC cold products contain acetaminophen, and taking additional acetaminophen creates risk of exceeding the 4 g/day maximum (or lower in hepatic impairment). Adding naproxen (A) ignores the acetaminophen duplication issue. Extended-release acetaminophen (C) doesn't address the fundamental problem of duplicate dosing. Niacin supplementation (D) has no role in preventing acetaminophen hepatotoxicity. The clinical framework is to always check all OTC combination products for hidden acetaminophen, especially in patients with liver disease or alcohol use, and limit total daily dose to 2-3 g in these patients.
  18. A 36-year-old man (78 kg) on sertraline 100 mg daily asks for an OTC product for a dry cough from a recent cold. He also takes sumatriptan as needed for migraines and has no allergies. Current OTC/supplements include dextromethorphan-containing cough syrup used yesterday. Which potential interaction should be assessed?
    Answer: Risk of serotonin syndrome with dextromethorphan combined with sertraline This question tests identification of OTC interactions with antidepressants. The key patient-specific factor is sertraline's serotonergic effects combined with dextromethorphan, risking syndrome. Risk of serotonin syndrome is most relevant because dextromethorphan inhibits serotonin reuptake, additive to SSRIs. Hypoglycemia (B) or absorption reduction (C) are misconceptions; kidney stones (D) lack association. A clinical pearl is monitoring for agitation or hyperthermia. A decision framework uses interaction severity ratings to guide avoidance.
  19. A 63-year-old woman (69 kg) with osteoporosis on alendronate asks whether she can take an OTC calcium supplement. She currently takes calcium carbonate 500 mg twice daily and also uses omeprazole 20 mg daily for reflux; allergies: none. Which action should the pharmacist take regarding this OTC product?
    Answer: Switch to calcium citrate at an equivalent elemental calcium dose because it is better absorbed with chronic proton pump inhibitor use This question tests calcium supplement optimization with PPIs. The key patient-specific factor is omeprazole reducing gastric acid, impairing calcium carbonate absorption. Switching to calcium citrate is best because it absorbs independently of acid, ensuring efficacy for osteoporosis. Continuing carbonate (B) or stopping (C) risks inadequacy; increasing dose (D) doesn't address absorption. Pharmacists should calculate elemental calcium needs. Guidelines recommend citrate forms with acid-suppressing therapy.
  20. A 58-year-old man (95 kg) with benign prostatic hyperplasia controlled on tamsulosin reports nasal congestion from a cold and asks for an OTC product. Medical history: hypertension; allergies: none. Current OTC/supplements include diphenhydramine 25 mg at bedtime for sleep and saw palmetto. Which OTC product is most appropriate for this patient?
    Answer: Oxymetazoline nasal spray 2–3 sprays per nostril twice daily for no more than 3 days This question tests OTC decongestant selection in patients with benign prostatic hyperplasia. The key patient-specific factor is BPH on tamsulosin, where systemic alpha-agonists may worsen urinary symptoms. Oxymetazoline nasal spray 2–3 sprays per nostril twice daily for no more than 3 days is most appropriate because it provides topical decongestion without systemic effects impacting BPH. Pseudoephedrine (A) and phenylephrine (implied in D, but D is chlorpheniramine) are suboptimal as they can exacerbate urinary retention; diphenhydramine (C) adds anticholinergic burden. A misconception is that all decongestants are equivalent, but topical are safer in BPH. Pharmacists should limit topical use to avoid rebound. Guidelines recommend assessing prostate symptoms before systemic agents.

Start this quiz